Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
CGTXCognition Therapeutics(CGTX) Newsfilter·2024-04-29 19:30

PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that the company has reached target enrollment in the randomized, placebo-controlled Phase 2 SHIMMER (COG1201) study (NCT05225415), which is examining the safety and effectiveness of CT1812 in adults with mild-to-moderate dementia with Lewy bodies (DLB). Top-line results are expected in  ...